Bisphosphonates regulate cell proliferation, apoptosis and pro-osteoclastic expression in MG-63 human osteosarcoma cells

Oncology Letters

Volumn 4, Issue 2, 2012, Pages 299-304

  Chang, Jun ^a   Wang, Wei ^a   Zhang, Hui ^a   Hu, Yong ^a   Yin, Zongsheng ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

Bisphosphonates; Osteoprotegerin; Osteosarcoma; Receptor activator of nuclear factor B ligand

Indexed keywords

4 [5 (4 METHYL 1 PIPERAZINYL)[2,5' BI 1H BENZIMIDAZOL] 2' YL]PHENOL; FLUORESCEIN ISOTHIOCYANATE; LIPOCORTIN 5; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PROPIDIUM IODIDE; ZOLEDRONIC ACID;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CELL GROWTH; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DOSE RESPONSE; ELECTRON MICROSCOPY; FLOW CYTOMETRY; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; OSTEOCLAST; OSTEOSARCOMA CELL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; S PHASE CELL CYCLE CHECKPOINT; TUMOR MICROENVIRONMENT; UPREGULATION; WESTERN BLOTTING;

EID: 84862279026     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2012.723     Document Type: Article

References (30)

1. Bacci G, Longhi A, Fagioli F, Briccoli A, Versari M and PicciP: Adjuvant and neoadjuvant chemotherapy for osteosarcoma of the extremities: 27 year experience at Rizzoli Institute, Italy. Eur JCancer 41: 2836-2845, 2005.
2. Perry CM and Figgitt DP: Zoledronic acid: a review of its use in patients with advanced cancer. Drugs 64: 1197-1211, 2004.
3. Green JR: Skelet al complications of prostate cancer: pathophysiology and therapeutic potential of bisphosphonates. Acta Oncol 44: 282-292, 2005.
4. Baulch-Brown C, Molloy TJ, Yeh SL, Ma D and Spencer A: Inhibitors of the mevalonate pathway as potential therapeutic agents in multiple myeloma. Leuk Res 31: 341-352, 2007.
5. Iguchi K, Nakano T, Usui S and Hirano K: Incadronate inhibits aminopeptidase N expression in prostatic PC-3 cells. Cancer Lett237: 223-233, 2006.
6. Nakajima H, Magae J, Tsuruga M, Sakaguchi K, Fujiwara I, Mizuta M, Sawai K, Yamagishi H and Mizuta N: Induction of mitochondria-dependent apoptosis through the inhibition of mevalonate pathway in human breast cancer cells by YM529, a new third generation bisphosphonate. Cancer Lett 253: 89-96, 2007.
7. Tassone P, Tagliaferri P, Viscomi C, Palmieri C, Caraglia M, D'Alessandro A, Galea E, Goel A, Abbruzzese A, Boland CR and Venuta S: Zoledronic acid induces antiproliferative and apoptotic effects in human pancreatic cancer cells in vitro. Br J Cancer 88: 1971-1978, 2003.
8. Im GI, Qureshi SA, Kenney J, Rubash HE and Shanbhag AS: Osteoblast proliferation and maturation by bisphosphonates. Biomaterials 25: 4105-4115, 2004.
9. Viereck V, Emons G, Lauck V, Frosch KH, Blaschke S, Gründker C and Hofbauer LC: Bisphosphonates pamidronate and zoledronic acid stimulate osteoprotegerin production by primary human osteoblasts. Biochem Biophys Res Commun 291: 680-686, 2002.
10. Wittrant Y, Théoleyre S, Chipoy C, Padrines M, BlanchardF, Heymann D and Rédini F: RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis. Biochim Biophys Acta 1704: 49-57, 2004.
11. Dougall WC and Chaisson M: The RANK/RANKL/OPG triad in cancer-induced bone diseases. Cancer Metastasis Rev 25: 541-549, 2006.
12. Baud'huin M, Duplomb L, Ruiz Velasco C, Fortun Y, Heymann D and Padrines M: Key roles of the OPG-RANK-RANKL system in bone oncology. Expert Rev Anticancer Ther 7: 221-232, 2007.
13. Plotkin LI, Manolagas SC and Bellido T: Dissociation of the pro-apoptotic effects of bisphosphonates on osteoclasts from their anti-apoptotic effects on osteoblasts/osteocytes with novel analogs. Bone 39: 443-452, 2006.
14. Green JR: Antitumor effects of bisphosphonates. Cancer 97: 840-847, 2003.
15. Horie N, Murata H, Nishigaki Y, Matsui T, Segawa H, NogawaM, Yuasa T, Kimura S, Maekawa T, Fushiki S and Kubo T: The third-generation bisphosphonates inhibit proliferation of murine osteosarcoma cells with induction of apoptosis. Cancer Lett 238: 111-118, 2006.
16. Koshimune R, Aoe M, Toyooka S, Hara F, Ouchida M, TokumoM, Sano Y, Date H and Shimizu N: Anti-tumor effect of bisphosphonate (YM529) on non-small cell lung cancer cell lines. BMC Cancer 7: 8, 2007.
17. Dickson PV, Hamner JB, Cauthen LA, Ng CY, McCarvilleMB and Davidoff AM: Efficacy of zoledronate against neuroblastoma. Surgery 140: 227-235, 2006.
18. Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD, Ebetino FH and Rogers MJ: Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther 296: 235-242, 2001.
19. Ishikawa C, Matsuda T, Okudaira T, Tomita M, KawakamiH, Tanaka Y, Masuda M, Ohshiro K, Ohta T and Mori N: Bisphosphonate incadronate inhibits growth of human T-cell leukaemia virus type I-infected T-cell lines and primary adult T-cell leukaemia cells by interfering with the mevalonate pathway. Br J Haematol 136: 424-432, 2007.
20. Caraglia M, Santini D, Marra M, Vincenzi B, Tonini G and Budillon A: Emerging anti-cancer molecular mechanisms of aminobisphosphonates. Endocr Relat Cancer 13: 7-26, 2006.
21. Ory B, Blanchard F, Battaglia S, Gouin F, Rédini F and HeymannD: Zoledronic acid activates the DNA S-phase checkpoint and induces osteosarcoma cell death characterized by apoptosis-inducing factor and endonuclease-G translocation independently of p53 and retinoblastoma status. Mol Pharmacol 71: 333-343, 2007.
22. Mori K, Le Goff B, Berreur M, Riet A, Moreau A, BlanchardF, Chevalier C, Guisle-Marsollier I, Léger J, Guicheux J, et al: Human osteosarcoma cells express functional receptor activator of nuclear factor-kappa B. J Pathol 211: 555-562, 2007.
23. Benassi MS, Chiechi A, Ponticelli F, Pazzaglia L, Gamberi G, Zanella L, Manara MC, Perego P, Ferrari S and Picci P: Growth inhibition and sensitization to cisplatin by zoledronic acid in osteosarcoma cells. Cancer Lett 250: 194-205, 2007.
24. Zhang J, Dai J, Qi Y, Lin DL, Smith P, Strayhorn C, MizokamiA, Fu Z, Westman J and Keller ET: Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J Clin Invest 107: 1235-1244, 2001.
25. Ishii R, Morimoto A, Ikushima S, Sugimoto T, Asami K, BesshoF, Kudo K, Tsunematu Y, Fujimoto J and Imashuku S: High serum values of soluble CD154, IL-2 receptor, RANKL and osteoprotegerin in Langerhans cell histiocytosis. Pediatr Blood Cancer 47: 194-199, 2006.
26. Mintz MB, Sowers R, Brown KM, Hilmer SC, Mazza B, HuvosAG, Meyers PA, Lafleur B, McDonough WS, HenryMM, et al: An expression signature classifies chemotherapy-resistant pediatric osteosarcoma. Cancer Res 65: 1748-1754, 2005.
27. Grimaud E, Soubigou L, Couillaud S, Coipeau P, Moreau A, Passuti N, Gouin F, Redini F and Heymann D: Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis. Am J Pathol 163: 2021-2031, 2003.
28. Quinn JE, Brown LG, Zhang J, Keller ET, Vessella RL and Corey E: Comparison of Fc-osteoprotegerin and zoledronic acid activities suggests that zoledronic acid inhibits prostate cancer in bone by indirect mechanisms. Prostate Cancer Prostatic Dis8: 253-259, 2005.
29. Tannehill-Gregg SH, Levine AL, Nadella MV, Iguchi H and Rosol TJ: The effect of zoledronic acid and osteoprotegerin on growth of human lung cancer in the tibias of nude mice. Clin Exp Metastasis 23: 19-31, 2006.
30. Zheng Y, Zhou H, Brennan K, Blair JM, Modzelewski JR, SeibelMJ and Dunstan CR: Inhibition of bone resorption, rather than direct cytotoxicity, mediates the anti-tumour actions of ibandronate and osteoprotegerin in a murine model of breast cancer bone metastasis. Bone 40: 471-478, 2007.